Regulatory Applications

Richmond Pharmacology will undertake all regulatory matters on behalf of our clients, depending on their requirements.

Our experienced project management team will compile all necessary documentation, including writing the information for volunteers, informed consent form and completing the online IRAS application form.

Richmond Pharmacology can obtain necessary documentation and specialist opinions for ethics submissions, in order to obtain approvals in a timely manner. We work closely with many ethics committees, local and nationwide, and will select an ethics committee based on study needs.

If required, the Principal Investigator will attend the ethics committee meeting to participate in discussions and ensure a smooth approval process.

As well as working with many Phase I ethics committees, we also work closely with our local ethics committee which approves Phase II studies. If required, we will obtain R&D approval for a specific site, a process of which Richmond Pharmacology has extensive experience.

Richmond Pharmacology will also organise and oversee the CTA application to the MHRA if required. We have submitted numerous CTAs to the MHRA on behalf of our clients, typically gaining approval after the first review of the study documentation.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more